FDA. (2014). Immunogenicity assessment for therapeutic protein products.

Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722–60. https://doi.org/10.1038/s41587-022-01582-x.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19(9):819–22. https://doi.org/10.1038/nbt0901-819.

Article  CAS  PubMed  Google Scholar 

Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10. https://doi.org/10.1016/j.ymeth.2005.01.001.

Article  CAS  PubMed  Google Scholar 

Masson GR, Burke JE, Ahn NG, Anand GS, Borchers C, Brier S, et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat Methods. 2019;16(7):595–602. https://doi.org/10.1038/s41592-019-0459-y.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323–7. https://doi.org/10.1038/332323a0.

Article  ADS  CAS  PubMed  Google Scholar 

Wang Y-MC, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Evaluating and reporting the immunogenicity impacts for biological products—a clinical pharmacology perspective. APPS J. 2016;18(2):395–403. https://doi.org/10.1208/s12248-015-9857-y.

Article  CAS  Google Scholar 

Krieckaert CLM, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12(5):217. https://doi.org/10.1186/ar3147.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12(7):703–8. https://doi.org/10.1016/j.autrev.2012.10.021.

Article  CAS  PubMed  Google Scholar 

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai W-C, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE. 2017;12(4): e0175207. https://doi.org/10.1371/journal.pone.0175207.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658–73. https://doi.org/10.1208/s12248-014-9599-2.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32. https://doi.org/10.1007/s13238-017-0408-4.

Article  MathSciNet  CAS  PubMed  Google Scholar 

Korswagen LA, Bartelds GM, Krieckaert CLM, Turkstra F, Nurmohamed MT, van Schaardenburg D, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheumat. 2011;63(4):877–83. https://doi.org/10.1002/art.30209.

Article  CAS  PubMed  Google Scholar 

Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000–2006. Biomed Mater Eng. 2009;19(4–5):355–64. https://doi.org/10.3233/bme-2009-0600.

Article  PubMed  Google Scholar 

Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, et al. A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci Transl Med. 2023;15(681):eabq5068. https://doi.org/10.1126/scitranslmed.abq5068.

Article  CAS  PubMed  Google Scholar 

Talotta R, Rucci F, Canti G, Scaglione F. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Immunother. 2019;11(3):241–54. https://doi.org/10.2217/imt-2018-0081.

Article  CAS  Google Scholar 

Shikh MEME, Sayed RME, Szakal AK, Tew JG. T-independent antibody responses to t-dependent antigens: a novel follicular dendritic cell-dependent activity. J Immunol. 2009;182(6):3482–91. https://doi.org/10.4049/jimmunol.0802317.

Article  CAS  PubMed  Google Scholar 

Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J Exper Med. 2006;203(2):305–10. https://doi.org/10.1084/jem.20052036.

Article  Google Scholar 

Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000;176(1):154–70. https://doi.org/10.1034/j.1600-065x.2000.00607.x.

Article  CAS  PubMed  Google Scholar 

Fischer SK, Cheu M, Peng K, Lowe J, Araujo J, Murray E, et al. Specific immune response to phospholipase b-like 2 protein, a host cell impurity in lebrikizumab clinical material. AAPS J. 2017;19(1):254–63. https://doi.org/10.1208/s12248-016-9998-7.

Article  CAS  PubMed  Google Scholar 

Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105(2):417–30. https://doi.org/10.1016/j.xphs.2015.11.002.

Article  CAS  PubMed  Google Scholar 

Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99–109. https://doi.org/10.3109/1547691x.2013.821564.

Article  CAS  PubMed  Google Scholar 

Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–7. https://doi.org/10.1208/aapsj080359.

Article  MathSciNet  PubMed Central  PubMed  Google Scholar 

Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708–14. https://doi.org/10.1016/j.copbio.2009.10.006.

Article  CAS  PubMed  Google Scholar 

Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol. 2002;169(11):6120–6. https://doi.org/10.4049/jimmunol.169.11.6120.

Article  CAS  PubMed  Google Scholar 

Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951. https://doi.org/10.3389/fimmu.2020.01951.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol. 2021;2(4):1004–20. https://doi.org/10.1039/d1cb00067e.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454–67. https://doi.org/10.1007/s11095-011-0621-4.

Article  CAS  PubMed  Google Scholar 

Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH*. J Clin Endocrinol Metab. 1980;51(4):691–7. https://doi.org/10.1210/jcem-51-4-691.

Article  CAS  PubMed  Google Scholar 

Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21(6):897–903. https://doi.org/10.1023/b:pham.0000029275.41323.a6.

Article  CAS  PubMed  Google Scholar 

Hu S, D’Argenio DZ. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling. J Pharmacokinet Pharmacodyn. 2020;47(5):385–409. https://doi.org/10.1007/s10928-020-09691-3.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity. 2007;40(2):131–7. https://doi.org/10.1080/08916930601165180.

Article  CAS  PubMed  Google Scholar 

Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the ‘altered self.’ Rheumatol. 2008;47(5):567–71. https://doi.org/10.1093/rheumatology/ken014.

Article  CAS